BRIEF-Samsara Vision To Initiate A U.S. Pma Supplemental Study Of The Sing Imt™, A New-Generation Technology For Age-Related Macular Degeneration
BRIEF-Samsara Vision To Initiate A U.S. Pma Supplemental Study Of The Sing Imt™, A New-Generation Technology For Age-Related Macular Degeneration
Brief-samsara Vision 將啓動一項針對年齡相關性黃斑變性的新一代技術 The Sing Imt™ 的美國 Pma 補充研究
* SAMSARA VISION INC - CONCERTO TRIAL WILL INCLUDE UP TO TWENTY CLINICAL SITES ACROSS UNITED STATESApril 20 (Reuters) - Samsara Vision Inc SMSA.O :
4 月 20 日（路透社）— Samsara Vision Inc SMSA.O：
* SAMSARA VISION TO INITIATE A U.S. PMA SUPPLEMENTAL STUDY OF THE SING IMT™, A NEW-GENERATION TECHNOLOGY FOR AGE-RELATED MACULAR DEGENERATION
* SAMSARA 願景將啓動美國 PMA 對 SING IMT™ 的補充研究，這是一種治療與年齡相關的黃斑變性的新一代技術
* SAMSARA VISION - ANNOUNCED FDA APPROVAL TO INITIATE U.S.-BASED, PMA SUPPLEMENTAL STUDY
* SAMSARA VISION——宣佈美國食品藥品管理局批准啓動總部位於美國的PMA補充研究
* SAMSARA VISION INC - CONCERTO TRIAL WILL INCLUDE UP TO TWENTY CLINICAL SITES ACROSS UNITED STATES
* SAMSARA VISION INC-CONCERTO 試驗將包括美國多達二十個臨床研究點
Source text for Eikon: ID:nBw5JsrLja Further company coverage: SMSA.O
Eikon 的來源文本：id: nbw5jsrlja 進一步的公司報道：SMSA.O
